Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60(1):78–83 Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15(1):93–99 Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A (2014) Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 38(4):329–338 Lian WQ, Luo F, Song XL, Lu YJ, Zhao SC (2015) Gonorrhea and prostate cancer incidence: an updated meta-analysis of 21 epidemiologic studies. Med Sci Monit 21:1902–1910 Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J et al (2015) Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncol Lett 9(3):1307–1312 Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ (2015) Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 21(4):756–762 Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12(2):130–135 Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7(1):169–170 Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77(3):219–225 Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7):1680–1691 Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA (2001) Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 158(5):1767–1773 Woenckhaus J, Fenic I (2008) Proliferative inflammatory atrophy: a background lesion of prostate cancer? Andrologia 40(2):134–137 Wang W, Bergh A, Damber JE (2009) Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 69(13):1378–1386 Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37(4):404–412 Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K et al (2002) Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 167(5):2267–2270 Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA et al (2003) Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43(2):164–175 Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR et al (2014) Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 23(5):847–856 Glass WG, Sarisky RT, Vecchio AM (2006) Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res 26(8):511–520 Cruikshank WW, Kornfeld H, Center DM (2000) Interleukin-16. J Leukoc Biol 67(6):757–766 Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M (1997) Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. Aids 11(4):485–491 Scala E, D’Offizi G, Rosso R, Turriziani O, Ferrara R, Mazzone AM et al (1997) C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 158(9):4485–4492 Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H (1998) Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 37(12):1334–1337 Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW (2002) Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 11(3):181–185 Kaufmann J, Franke S, Kientsch-Engel R, Oelzner P, Hein G, Stein G (2001) Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology 40(4):474–475 Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA et al (2008) Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 58(5):1465–1474 Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A et al (2004) Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol 75(2):101–106 Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H et al (2009) The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 30(2):295–299 Comperat E, Roupret M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A et al (2010) Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate 70(15):1622–1627 Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S et al (2000) Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 100(1):63–69 Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899 Gohagan JK, Prorok PC, Hayes RB, Kramer BS (2000) The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21(6 Suppl):251 s-272 s Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N et al (2000) Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21(6 Suppl):349s–355s Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB et al (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 41(10):1055–1057 Huang WY, Hayes R, Pfeiffer R, Viscidi RP, Lee FK, Wang YF et al (2008) Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomark Prev 17(9):2374–2381 Tuzova M, Richmond J, Wolpowitz D, Curiel-Lewandrowski C, Chaney K, Kupper T et al (2015) CCR4 + T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leuk Lymphoma 56(2):440–449 Yellapa A, Bitterman P, Sharma S, Guirguis AS, Bahr JM, Basu S et al (2014) Interleukin 16 expression changes in association with ovarian malignant transformation. Am J Obstet Gynecol 210(3):272.e1-10 Purzycka-Bohdan D, Szczerkowska-Dobosz A, Zablotna M, Wierzbicka J, Piotrowska A, Zmijewski MA et al (2016) Assessment of interleukin 16 serum levels and skin expression in psoriasis patients in correlation with clinical severity of the disease. PLoS ONE 11(10):e0165577 Nischwitz S, Faber H, Samann PG, Domingues HS, Krishnamoorthy G, Knop M et al (2014) Interferon beta-1a reduces increased interleukin-16 levels in multiple sclerosis patients. Acta Neurol Scand 130(1):46–52 Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW et al (2005) Anti-IL-16 therapy reduces CD4 + T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 79(5):680–693 Paalani M, Lee JW, Haddad E, Tonstad S (2011) Determinants of inflammatory markers in a bi-ethnic population. Ethn Dis 21(2):142–149 Morimoto Y, Conroy SM, Ollberding NJ, Kim Y, Lim U, Cooney RV et al (2014) Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes 38(11):1416–1422 Fisher G, Hyatt TC, Hunter GR, Oster RA, Desmond RA, Gower BA (2012) Markers of inflammation and fat distribution following weight loss in African-American and white women. Obesity 20(4):715–720 Stowe RP, Peek MK, Cutchin MP, Goodwin JS (2010) Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol A Biol Sci Med Sci 65(4):429–433 Contreras-Sesvold C, Revenis BD, O’Connor FG, Deuster PA (2015) Association of plasma heat shock protein 70, interleukin 6, and creatine kinase concentrations in a healthy, young adult population. J Biomark 2015:967120 Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA (2006) Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15(11):2160–2166 Patel DA, Bock CH, Schwartz K, Wenzlaff AS, Demers RY, Severson RK (2005) Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case–control study in Wayne County, Michigan. Cancer Causes Control 16(3):263–273 Pelucchi C, Talamini R, Negri E, Franceschi S, La Vecchia C (2006) Genital and urinary tract diseases and prostate cancer risk. Eur J Cancer Prev 15(3):254–257 De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG et al (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269 McDonald AC, Vira MA, Vidal AC, Gan W, Freedland SJ, Taioli E (2014) Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease—the 2001–2008 National Health and Nutrition Examination Survey. Prostate 74(5):561–567 Elzanaty S, Rezanezhad B, Borgquist R (2016) Association between PSA Levels and biomarkers of subclinical systemic inflammation in middle-aged healthy men from the general population. Curr Urol 9(3):148–152